Our great stories can become your next great story when you learn about the exciting, world-class medicine that is being developed and delivered at the University of Maryland Medical Center!
Check this page often for timely updates about the most current life-saving medical advances and treatments happening at UMMC. And then reach out to a member of the media team to help you schedule interviews and video for your next great story.
GammaPod is a new treatment option for early stage breast cancer invented here at the University of Maryland School of Medicine.
Targeted radiation treatment is delivered in less treatments and spares radiation exposure to other organs including the heart and lungs.
The University of Maryland Medical Center Downtown Campus in Baltimore is the first place in the country to offer this innovative new treatment.
Learn more about GammaPod:
MRI-Guided Focused Ultrasound
With the potential to transform the treatment of many medical disorders by using ultrasonic energy to target tissue deep in the body without incisions or radiation, focused ultrasound is an early-stage, non-invasive therapeutic technology offering new hope to patients.
University of Maryland Medical Center physician scientists are pioneering the use of MRI-guided focused ultrasound to become a new standard of care for treating many common and devastating brain diseases including Parkinson's, essential tremor, neuropathic pain and glioblastoma, an often deadly type of brain cancer.
- Focused Ultrasound to Treat Parkinson's Disease | Press Release
- Focused Ultrasound to Open Blood-Brain Barrier | Press Release
- Man Finds Golf Swing After Essential Tremor Treatment | Patient Story
- ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease
- Second clinical trial to test the safety and efficacy of using MRI-guided focused ultrasound on the brain in order to treat Parkinson's disease
- Clinical trial for glioblastoma which uses MRI-guided focused ultrasound
Stem Cell Research
Can adult stem cells derived from bone marrow benefit children with the congenital heart defect hypoplastic left heart syndrome (HLHS)?
That is what Sunjay Kaushal, MD, PhD, professor of surgery at the University of Maryland School of Medicine and director, pediatric cardiac surgery, University of Maryland Children’s Hospital, is leading research to find out.
In HLHS, the left ventricle does not develop completely during a critical growth period just prior to birth. The hope is that the stem cells improve the heart’s pumping ability.